enVVeno Medical Corp Earnings Per Share Disclosure
| December 31, | ||||||||
| (In thousands) | 2024 | 2023 | ||||||
| Shares of common stock issuable upon exercise of warrants | 9,846 | 14,392 | ||||||
| Shares of common stock issuable upon exercise of options | 6,322 | 5,185 | ||||||
| Potentially dilutive common stock equivalents excluded from diluted net loss per share | 16,168 | 19,577 | ||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.